Archive September 11, 2017 Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress
Archive September 5, 2017 Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma
Archive August 31, 2017 Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress
Archive June 5, 2017 Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting
Archive June 1, 2017 Deciphera Pharmaceuticals Announces $52 Million Series C Financing to Advance Novel Clinical-stage Oncology Pipeline
Archive May 18, 2017 Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting
Archive April 3, 2017 Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations
Archive March 16, 2017 Deciphera Pharmaceuticals to Present at 27th Annual Oppenheimer Healthcare Conference
Archive March 7, 2017 Deciphera Pharmaceuticals to Report Translational Research Findings with DCC-2618 at the 2017 American Association for Cancer Research (AACR) Annual Meeting
